RxDoctor Payments Data

Sylvia Falls, MD

Hematology & Oncology · Orland Park, ILNPI 1528231750

Payments from drug & device makers

$15,211in general payments, 2019–2025

Across 24 payments — averaging $633.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$8K
  • Merck$3K
  • AstraZeneca$3K
  • Daiichi Sankyo Inc.$400
  • Pfizer$145
  • Johnson & Johnson$122
  • plus $417 from 8 others

What the payments were for

  • Consulting fees$9,39079%
  • Travel & lodging$1,73015%
  • Food & beverage$6976%
  • Education$290%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,211 in reported general payments places this provider in the 55th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$95,427
Medicare patients
296
Services billed
951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib32$509,369
ImbruvicaIbrutinib11$169,012
EliquisApixaban83$71,418
XareltoRivaroxaban12$14,503
Anastrozole404$5,583
Prochlorperazine Maleate69$1,199
Hydroxyurea18$832
Letrozole37$559
Tamoxifen Citrate14$435
Ondansetron Hcl30$430
Pregabalin21$405
Dexamethasone48$396
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine13$313
LoperamideLoperamide Hcl23$271
Acyclovir27$222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$145$580,787115 claims
Johnson & JohnsonXarelto$122$14,50312 claims
Lilly USA, LLCOlanzapine$60$1911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Orland Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →